TTNP
Esta tiene hoy noticia de ADCOM, eso unido a que va por la tercera con 3 ensayos para lo mismo y una noticia de pumpeo por técnico en TheStreet hace de ella una oportunidad de largo rápido para empapelar personal.
Titan Pharmaceuticals and Braeburn Pharmaceuticals Announce Date of FDA Advisory Committee Review of Probuphine for Opioid Addiction
http://finance.yahoo.com/news/titan-pharmaceuticals-braeburn-pharmaceuticals-announce-120000953.html
The Street
Titan Pharmaceuticals (TTNP - Get Report) , a specialty pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders in the U.S. This stock traded up 1.9% to $5.30 in Tuesday's trading session.
From a technical perspective, Titan Pharmaceuticals spiked modestly higher here and showed relative strength compared with the overall market weakness with strong upside volume flows. This stock has experienced a number of above-average volume days combined with share price strength over the last few weeks. This high-volume move to the upside on Tuesday is now quickly pushing shares of Titan Pharmaceuticals within range of triggering a major breakout trade above some key near-term overhead resistance levels. That breakout will trigger if this stock manages to take out some near-term overhead resistance levels at $5.44 to $5.62 a share with high volume.
Traders should now look for long-biased trades in Titan Pharmaceuticals as long as it's trending above its 20-day moving average of $4.54 or its 50-day moving average of $4.35 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 48,681 shares. If that breakout materializes soon, then this stock will set up to re-test or possibly take out its next major overhead resistance level at $10 a share.
CARA
La vi hace un rato con un + veintipico por ciento en pre y con una noticia que no daba para tanto, pero tiene más de un 68% de institucionales, así que no hice corto, pero está para observarla
OCUL
No sé cómo se comporta, pero no vale para mucho y acaba de anunciar presentación de IND a la FDA. No obstante, tiene un gap que igual le podría ir a dar por cerrar.
«Después de nada, o después de todo/ supe que todo no era más que nada.»